{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:35:00Z","timestamp":1784248500211,"version":"3.55.0"},"reference-count":48,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2020,6,2]]},"DOI":"10.1080\/13696998.2020.1722138","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T16:14:28Z","timestamp":1580141668000},"page":"631-640","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada"],"prefix":"10.1080","volume":"23","author":[{"given":"Karissa","family":"Johnston","sequence":"first","affiliation":[{"name":"Broadstreet Health Economics and Outcomes Research, Vancouver, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Danchenko","sequence":"additional","affiliation":[{"name":"Ipsen Global, Boulogne-Billancourt, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hansen","sequence":"additional","affiliation":[{"name":"Choice Institute, University of Washington, Seattle, WA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Dinet","sequence":"additional","affiliation":[{"name":"Ipsen Biopharmaceuticals Canada, Mississauga, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Liovas","sequence":"additional","affiliation":[{"name":"Ipsen Biopharmaceuticals Canada, Mississauga, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Ipsen Biopharmaceuticals Canada, Mississauga, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savreet","family":"Bains","sequence":"additional","affiliation":[{"name":"Ipsen US, Basking Ridge, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Choice Institute, University of Washington, Seattle, WA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.siny.2005.10.010"},{"key":"CIT0002","unstructured":"Abdel-Hamid HZ, Bazzano ATF, Ratanawongsa B. Cerebral Palsy. Medscape. 2018. [cited 2020 Jan 31]. Available from https:\/\/emedicine.medscape.com\/article\/1179555-overview"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtumed.2012.12.004"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S86978"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2006.09.009"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2011.12.001"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4845"},{"key":"CIT0008","unstructured":"NICE. Clinical guideline [CG145] spasticity in under 19s: management. National Institute for Health and Care Excellence; 2012; [updated Nov 2016; cited 2019 Oct 22]. Available from: https:\/\/www.nice.org.uk\/guidance\/CG145"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.3390\/toxins7051629"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03126.x"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/67.2.206"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1017\/S0012162206000132"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1007\/BF01530764"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0205-4"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100014049"},{"issue":"4","key":"CIT0016","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1212\/WNL.0b013e3181cbcd2f","volume":"74","author":"Delgado MR","year":"2010","journal-title":"Neurology"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1177\/0883073817729918"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-2830"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1177\/0883073816686910"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.1265"},{"issue":"2","key":"CIT0021","first-page":"63","volume":"79","author":"Inotai A","year":"2009","journal-title":"Acta Pharm Hung"},{"key":"CIT0022","volume-title":"Decision modelling for health economic evaluation","author":"Andy Briggs KC","year":"2006"},{"key":"CIT0023","volume-title":"Guidelines for the economic evaluation of health technologies","author":"Canadian Agency for Drugs and Technologies in Health.","year":"2017","edition":"4"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-0016"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.1410"},{"key":"CIT0026","unstructured":"Statistics Canada. Life Tables, Canada, Provinces and Territories (84-537-X); 2017. [cited 2018 Oct 24]. Available from: http:\/\/www5.statcan.gc.ca\/olc-cel\/olc.action?objId=84-537-X&objType=2&lang=en&limit=0"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12718"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1177\/0883073819830579"},{"issue":"15","key":"CIT0029","first-page":"S29.007","volume":"90","author":"Kim H","year":"2018","journal-title":"Neurology"},{"key":"CIT0030","unstructured":"Ipsen Biopharmaceuticals. Product Monograph. PrDYSPORT THERAPEUTIC\u2122 abobotulinumtoxinA for injection Ph. Eur. Ipsen Biopharm Limited; 2018; [cited 2018 Oct 24]. Available from: https:\/\/ipsen.com\/websites\/IPSENCOM-PROD\/wp-content\/uploads\/sites\/18\/2018\/11\/08151628\/dysport-therapeutic-pm-Oct.24.2018_EN.pdf"},{"key":"CIT0031","volume-title":"BOTOX (onabotulinumtoxinA) prescribing information","author":"Allergen Pharmaceuticals","year":"2019"},{"key":"CIT0032","unstructured":"National Center for Health Statistics. US Centers for Disease Control and Prevention. Weight for age charts; 2000. [cited 2018 Oct 24]. Available from: https:\/\/www.cdc.gov\/growthcharts\/percentile_data_files.htm"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0153-y"},{"key":"CIT0034","unstructured":"NICE. Glossary. National Institute for Health and Care Excellence; 2013; [cited 2019 Nov 5]. Available from: https:\/\/www.nice.org.uk\/glossary?letter=q"},{"key":"CIT0035","doi-asserted-by":"crossref","unstructured":"Eckwright D, Burke J, Gleason P. Real-world botulinum toxin (BT) utilization and treatment cost for cervical dystonia (CD) and limb spasticity (LS). Academy of Managed Care Pharmacy\u2019s (AMCP) Managed Care & Specialty Pharmacy Nexus Meeting; Oct 29 to Nov 1; 2019.","DOI":"10.18553\/jmcp.2019.25.3-a.s1"},{"key":"CIT0036","doi-asserted-by":"crossref","unstructured":"Turner-Stokes L, Ashford S, Fheodoroff K, et\u00a0al. Time to retreatment with botulinum toxin A in upper limb spasticity management: upper limb international spasticity (ULIS)-III study interim analysis. Paper presented at: Toxins; 2019 Jan 16\u201319; Copenhagen, Denmark; 2019.","DOI":"10.1016\/j.toxicon.2018.11.266"},{"key":"CIT0037","unstructured":"Ipsen Biopharmaceuticals. DYSPORT THERAPEUTIC\u2122 Product Monograph. AbobotulinumtoxinA for injection Ph. Eur. Mississauga, ON; 2018."},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2018.01.023"},{"issue":"5","key":"CIT0039","first-page":"412","volume":"40","author":"Tapias G","year":"2016","journal-title":"Farm Hosp"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.2340\/16501977-2550"},{"key":"CIT0041","unstructured":"Al-Mazraawy B. Potential cost savings were identified across the Yale Health System when primarily using Dysport\u00aevs. Botox\u00ae. 53rd Annual ASHP Midyear Clinical Meeting; 2018 Dec 2\u20136; Anaheim, CA."},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.30809\/phe.3.2015.5"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514566416"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1177\/0269215508101742"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.3310\/hta10460"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08962.x"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2014.999283"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04033.x"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2020.1722138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:51:59Z","timestamp":1665622319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2020.1722138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,2]]}},"alternative-id":["10.1080\/13696998.2020.1722138"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2020.1722138","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}